Pharma BD Deal Intelligence

Biogen Inc. / Human Immunology Biosciences

2024 · Acquisition/Merger · $1.1B · Complete

Announcement Sentiment

88

Strongly positive

Outcome Score

68

Largely worked — most objectives met.

Biogen acquired HI-Bio for $1.15B for monoclonal antibody pipeline.

Key facts

Announced May 22, 2024
Closed Jul 02, 2024
Deal value $1.1B
Deal type Acquisition/Merger
Therapeutic area Immunology, Nephrology
Key assets felzartamab

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals